Table 2.
Overview of local control and toxicity in prospective trials using intensity modulated radiotherapy (IMRT)
| Study | Year | Patients | RT-margins | LPFS | Toxicity (≥ II) |
|---|---|---|---|---|---|
| Alektiar et al. | 2007 | neo: 7 adj: 24 |
a: 2 cm l: 5 cm |
2y 95% | Dermatitis: 26% Edema: 13% Joint stiffness: 19% Neuropathy: 5% Wound Complication: 9.6% Fractures: 6.4% |
| Alektiar et al. | 2008 | neo: 7 adj: 34 |
a: 2 cm l: 3 cm |
5y 95% | Edema: 12.2% Joint sitffness: 17.1% Wound complication: 9.9% chronic: Dermatitis: 1.9% Fractures: 4.8% |
| O’Sullivan et al. | 2013 | neo: 59 | a: 1.5 cm l: 4 cm |
5y 88% | Wound complications: 30.4% chronic: Edema: 11.1% Joint stiffness: 5.6% Fractures: 0% |
| Folkert et al. | 2014 | adj: 165 | a: 1–1.5 cm l: 3–4 cm |
5y 93% | Dermatitis: 31.5% Edema: 8% Joint stiffness: 14.5% chronic: Joint stiffness: 12.5% Fracture: 7.9% |
| Wang et al. | 2015 | neo: 42a | high grade: a:1.5, l: 3 cm low grade: a:1 cm, l: 2 cm |
2y 89% |
chronic:
Edema, joint stiffness or fibrosis: 11.9% |
label: a axial, adj adjuvant, neo neoadjuvant, LPFS Local progression free survival, l longitudinal, RT radiotherapy, y year
apartially combined with chemotherapy